Glucocorticoids and Th-1, Th-2 type cytokines in rheumatoid arthritis, osteoarthritis, asthma, atopic dermatitis and AIDS

Clinical and Experimental Rheumatology

Volumn 15, Issue 3, 1997, Pages 315-323

  Norbiato, G ^a   Bevilacqua, M ^a   Vago, T ^a   Clerici, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

AIDS; Atopic dermatitis; Bronchial asthma; Cytokines of the Th 1; Glucocorticoid receptor; Glucocorticoids; Osteoarthritis; Rheumatoid arthritis; Th 2 subtype HIV

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CYTOKINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ASTHMA; ATOPIC DERMATITIS; B LYMPHOCYTE; CARTILAGE CELL; CORTICOSTEROID RELEASE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; OSTEOARTHRITIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; RHEUMATOID ARTHRITIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ARTHRITIS, RHEUMATOID; ASTHMA; CYTOKINES; DERMATITIS, ATOPIC; GLUCOCORTICOIDS; HUMANS; OSTEOARTHRITIS;

EID: 0030910707     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. MUNCK A, GUYRE PM: Glucocorticoid physiology, pharmacology and stress. In: CHROUSOS GP, LORIAUX DL, LIPSETT MB (Eds.): Steroid Hormone Resistance. Mechanisms and Clinical Aspects. Advances in Experimental Medicine and Biology, Vol. 196, New York, Plenum Press, 1986: 81-96.
2. LAUE L, KAWAI S, BRANDON D, KNAZEK R, LORIAUX DL, CHROUSOS GP: Receptor-mediated effects of glucocorticoids on inflammation: enhancement of the inflammatory response with a glucocorticoid antagonist. J Steroid Biochem Mol Biol 1988; 29: 591-8.
3. ZACHARCHUK CM, MERCEP M, CHAKRABORTI PK, SIMONS SS JR, ASHWELL JD: Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonist. J Immunol 1990; 145: 4037-45.
4. PARRILLO JE, FAUCI AS: Mechanisms of glucocorticoid action on immune processes. Annu Rev Pharmacol Toxicol 1979; 19: 179-201.
5. GILLIS S, CRABTREE GR, SMITH KA: Glucocorticoid-induced inhibition of T cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol 1979; 123: 1624-31.
6. ARYA SK, WONG-STAAL F, GALLO RC: Dexamethone-merdiated inhibition of human T cell growth factor and γ-interferon mRNA. J Immunol 1984; 133: 273-6.
7. ROBB RJ, KUTNY RM: Structure-function relationship for the IL-2 receptor system. J Immunol 1987; 139: 855-62.
8. SMITH KA: Interleukin-2: inception, impact, and implications. Science (Wash., DC) 1988; 24: 1169-76.
9. FROLIK CA, DART LL, MEYERS CA, SMITH EM, SPORM MB: Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci USA 1983; 80: 3676-80.
10. ROBERTS AB, SPORN MB: The transforming growth factorbeta. In: SPORN MB, ROBERTS AB (Eds.): Peptide Growth Factors and Their Receptors, Springer-Verlag, Heidelberg, 1990.
11. SAXON A, STEVENS RH, RAMER SJ, CLEMENTS PJ, YOU DTY: Glucocorticoids administered in vivo inhibit human suppressor T lymphocyte function and diminish B lymphocyte responsiveness to in vitro immunoglobulin synthesis. J Clin Invest 1978; 61: 922-30.
12. FONTANA A, FREI K, BOOMER S, HOFER E, SCHREIER MH, PALLADINO MA JR ZINKERNAGEL RM: Transforming growth factor-β inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 1989; 143: 3230-4.
13. VACCA A, FELLI MP, FARINA AR, et al: Glucocorticoid receptor mediated suppression of the interleukin-2 gene expression through impairment of the cooperativity between nuclear factors or activated T cells and AP 1 enhancer elements. J Exp Med 1992; 175: 637-46.
14. DAYNES RA, ARANEO BA: Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin-2 and interleukin-4. Eur J Immunol 1989; 19: 2319-25.
15. WU CY, SARFATI M, HEUSSER C, et al.: Glucocorticoids increase the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clin Invest 1991; 87: 870-7.
16. IMURA H, FUKATA J, MORI T: Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin Endocrinol (Oxf) 1991; 35: 107-15.
17. WOLOSKI BM, SMITH EM, MEYER WJ, FULLER GM, BLALOCK JE: Corticotropin-releasing activity of monokines. Science 1985; 230: 1035-7.
18. HARBUZ MS, STEPHANOU A, SARLIS N, LIGHTMA SL: The effects of recombinant interleukin (IL)-1 alpha, IL-1 beta or IL6 on the hypothalamo-pituitary-adrenal axis activation. J Endocrinol 1992; 133: 349-55.
19. LYSON K, MCCANN SM: The effect of interleukin-6 on pituitary hormone release in vivo and in vitro. Neuroendocrinology 1991; 54: 262-6.
20. CHIKANZA IAN C, PETROU P, KINGSLEY G, CHROUSOS G, PANAYI SG: Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 1281-8.
21. NEECK G, FEDERLIN K, GRAEF V, RUSCH D, SCHMIDT K: Adrenal secretion of cortisol in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 24-9.
22. SCHLAGHECKE R, KORNELY E, WOLLENHAUPT J, SPECKER C: Glucocorticoid receptors in rheumatoid arthritis. Arthritis Rheum 1992; 35: 740-4.
23. KIRKHAM BW, CORKHILL MM, DAVISON SC, PANAYI GS: Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell-mediated immune assay predicts in vivo responses. J Rheumatol 1991; 18: 821-5.
24. SNOWDEN N, KAY RA: Immunology of systemic rheumatoid disease. Br Med Bull 1995; 51: 437-8.
25. COHEN SB, KATSIKIS PD, CHU CQ, THOMSSEN H, WEBB LM, MAINI RN, LONDEI M, FELDMANN M: High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum 1995; 38: 946-52.
26. SCHULZE-KOOPS H, LIPSKY PE, KAVANAUGH AF, DAVIS LS: Elevated Th1-or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol 1995; 155: 5029-37.
27. PELLETIER JP, MARTEL-PELLETIER J, MALEOUD CJ: Canine osteoarthritis: effects of endogenous neutral metalloproteoglycanases on articular cartilage proteoglyvans. J Orthop Res 1988; 6: 379-88.
28. MARTEL-PELLETIER J, PELLETIER JP, CLOUTIER JM, HOWELL DS, GHANDUR-MNAYMNEH L, WOESSNER JF, JR: Neutral proteases capable of proteglycan digesting activity in osteoarthritic and normal human articular cartilage. Arthritis Rheum 1984; 27: 305-12.
29. PELLETIER JP, MARTEL-PELLETIER J, HOWELL DS, GHANDUR-MNAYMNEH L, ENIS JE, WOESSNER JF, JR: Collagenase and collagenolytic activiy in human osteoarthritic cartilage. Arthritis Rheum 1983; 26: 63-8.
30. PELLETIER JP, MARTEL-PELLETIER J, ALTMAN RD, GHANDUR-MNAYMNEH L, HOWELL DS, WOESSNER JF, JR: Collagenolytic activity and collagen matrix breakdown of the articular cartilage in the Pond-Nuki dog model of osteoarthritis. Arthritis Rheum 1983; 26: 866-74.
31. DURUM SK, SCHMIDT JA, OPPENHEIM JJ: Interleukin 1 : An immunological perspective. Annu Rev Immunol 1985; 3: 263-87.
32. PELLETIER JP, MARTEL-PELLETIER J, CLOUTIER JM, WOESSNER JF, JR: Proteoglycan-degrading acid metalloprotease activity in human osteoarthritic cartilage, and the effect of intra-articular steroid injections. Arthritis Rheum 1987; 30: 541-8.
33. MCGUIRE-GOLDRING MKB, MURPHY G, GOWEN M, et al.: Effects of retinol and dexamethasone on cytokine-mediated control of metalloproteinases and their inhibitors in human articular chondrocytes and synovial cells in culture. Biochim Biophys Acta 1983; 763: 129-39.
34. DI BATTISTA JA, MARTEL-PELLETIER J, WOSU OL, SANDOR T, ANTAKLY T, PELLETIER JP: Glucocorticoid receptor mediated inhibition of interleukin-1 stimulated neutral metalloprotease synthesis in normal human chondrocytes. J Clin Endocrinol Metab 1991; 72: 316-26.
35. DI BATTISTA JA, MARTEL-PELLLETTIER J, AUTAKLY T, TARDIF G, CLOUTIER GM, PELLETIER GP: Reduced expression of glucocorticoid receptor level in human osteoarthritic chondrocytes. Role in the suppression of metalloprotease synthesis. J Clin Endocrinol Metab 1993; 76: 1128-34.
36. REED CE: Basic mechanisms of asthma, role of inflammation. Chest 1988; 94: 175-7.
37. CLARK TJH, HETZEL MR : Diurnal variation of asthma. Br J Dis Chest 1977; 94: 175-7.
38. KALLENBACH JM, PANZ VR, JOFFE BI, JANKELOW D, ANDERSON R, HAITAS B, SEFTEL HC: Nocturnal events related to morning dipping in bronchial asthma. Chest 1988; 93: 751-7.
39. BARNES P, FITZGERALD G, BROWN M, DOLLERY C: Nocturnal asthma and changes in circulating epinephrine, histamine, and Cortisol. New Engl J Med 1980; 303: 263-7.
40. NASERT S, MILLNER M, HERZ U, LACK G, WAHN U, GELFAND EW, RENZ H: Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt 1995; 118-30.
41. KAWANO Y, NOMA T: Dual Action of IL-4 on mite antigen-induced IgE synthesis in lymphocytes from individuals with bronchail asthma. Clin Exp Immunol 1995; 86: 389-94.
42. SCHWARTZ HJ, LOWELL FC, MELBY JC: Steroid resistance in bronchial asthma. Ann Intern Med 1968; 69: 493-9.
43. CARMICHAEL J, PATERSON IC, DIAZ P, CROMPTON GE, KAY AB, GRANT IWB: Corticosteroid resistance in chronic asthma. Br Med J 1981; 282: 1419-22.
44. CORRIGAN CJ, BROWN PH, BARNES NC, TSAI JJ, FREW AJ, KAY AB: Glucocorticoid resistance in chronic asthma. Am Rev Resp Dis 1991; 144: 1016-25.
45. ALVAREZ J, SURS W, LEUNG DYM, IKLÉ D, GELFAND EW, SZEFLER SJ: Steroid-resistant asthma: immunologic and pharmacologic features. J Allergy Clin Immunol 1992; 89: 714-21.
46. H2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298-304.
47. H2 subsets: doubt no more. Immunol Today 1991; 12: 256-62.
48. SHER ER, SURS W, KAM JC, KAMADA AK, HARBECK R, LEUNG DYM, SZEFLER SJ: Characterization of T lymphocytes and glucocorticoid receptors in steroid resistant asthma. J Allergy Clin Immunol 1992; 89: 285-92.
49. CASTRO M, LEUNG DY, KARL M, ELLIOT S, SZEFLER SJ, KINO T, CHROUSOS GP: Changes in the alternative splicing of the glucocorticoid gene might contribute to the pathogenesis of steroid-resistant asthma. 10th International Congress on Endocrinology, 1996, San Francisco, P3-649 (abst.).
50. WÜTHRICH B: Serum IgE in atopic dermatitis. Clin Allergy 1978; 8: 241-8.
51. LOBITZ WC, HONEYMAN JF, WINKLER NW: Suppressed cell-mediated immunity in two adults with atopic dermatitis. Br J Dermatol 1972; 86: 317-28.
52. VAN DE KERKHOF PCM: Plasma aldosterone and cortisol levels in psoriasis and atopic dermatitis. Br J Dermatol 1981; 106: 423-8
53. HAMID O, NASEER T, MINSHALL EM, SONG YL, BOGUNIEWICZ M, LEUNG DY: In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996; 98: 225-31.
54. RUPPRECHT M, RUPPRECHT R, KORNHUBER J, WODARZ N, KOCH HU, RIEDERER P, HORNSTEIN OP: Elevated glucocorticoid receptor in concentrations before and after glucocorticoid therapy in perhipheral mononuclear leukocytes of patients with atopic dermatitis. Dermatologica 1991; 183: 100-5.
55. CLAYTON MH, LEUNG DY, SURS W, SZEFLER SJ: Altered glucocorticoid receptor binding in atopic dermatitis. J Allergy Clin Immunol 1996; 96: 421-3.
56. GRINSPOON SK, BILEZIKIAN JP: HIV disease and the endocrine system. N Engl J Med 1992; 327: 1360-5.
57. CHRISTEFF N, GHARAKHANIAN S, THOBIE N, et al.: Evidence of changes in adrenal and testicular steroids during HIV infection. J Acq Immun Defic 1992; 5: 841-6.
58. TANG WW, KAPTEIN E, FEINSTEIN EI, MASSRY SG: Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am J Med 1993; 94: 169-74.
59. CLERICI M, SHEARER GM: A TH1 TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14: 107-11.
60. CHEHIMI J, TRINCHIERI G, FRANK I, et al.: IL-12 deficiency in HIV-infected patients. J Exp Med 1994; 179: 1361-6.
61. CLERICI M, WYNN TA, BERZOFSKY JA, et al.: Role of interleukin-10 (IL-10) in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus (HIV-1). J Clin Invest 1994; 93: 768-75.
62. MANETTI R, PARRONCHI P, GIUDIZI MG, et al.: Natural killer stimulatory factor (IL-12) induces T helper type 1 (Th-1) specific-response and inhibits the development of IL-4 producing Th cells. J Exp Med 1993; 177: 1199-204.
63. SEDER RA, PAUL WE, DAVIS MM, et al.: The presence of interleukin-4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992; 176: 1091-8.
64. CLERICI M, BEVILACQUA M, VAGO T, VILLA ML, SHEARER GM, NORBIATO G: An immunological hypothesis of HIV infection. Lancet 1994; 343: 1552-3.
65. NORBIATO G, BEVILACQUA M, VAGO T, BALDI G, CHEBAT E, BERTORA P, MORONI M, GALLI M, OLDENBURG N: Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 608-13.
66. NORBIATO G, BEVILACQUA M, VAGO T, CLERICI M: Glucocorticoids and interferon-α in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1996; 81: 2601-6.
67. FELDMAN SB, MILONE MC, KLOSER P, BOCARSLY FP: Functional deficiencies in two distinct interferon alpha-producing cell in HIV virus sieropositive patients. J Leukocyte Biol 1995; 57: 214-20.
68. HOWELL DM, FELDMAN SB, KLOSER P, BOCARSLY FP: Decreased frequency of functional natural interferon-producing cells in peripheral blood of patients with the acquired immunodeficiency syndrome. Clin Immunol Immunopathol 1994; 71: 223-30.
69. GENDELMAN HE, ORENSTEIN JM, BACA LM, et al.: The macrophage in the persistence and pathogenesis of HIV infection. AIDS 1989; 3: 475-95.
70. ROY S, WAINBERG MA: Role of the mononuclear phagocyte system in the development of acquired immunodeficiency syndrome (AIDS). J Leukocyte Biol 1988; 43: 91-7.
71. DUPONE T, HUYGEN K, SCHANDENS L, VANDERSCUYA M, PALFLIET K, WYBREN J: Influence of in vivo immunosuppressive drugs on production of lymphokines. Transplantation 1985; 39: 148-52
72. ROSSOL S, VOTH R, LAUBENSTEIN HP, et al.: Interferon production in patients infected with HIV-1. J Infect Dis 1989; 150: 815-21.
73. ROOSTH J, POLLARD RB, BROWN SL, MEYER II WJ: Cortisol stimulation by recombinant interferon-alpha 2. J Neuroimmunol 1986; 12: 311-6.
74. MULLER H, HAMMES E, HIEMKE C, HESS G: Interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man. Neuroendocrinology 1991; 54: 499-503.
75. + cells. J Exp Med 1993; 178: 1655-63.
76. AKIRA S, HIRANO T, TAGA T, KISHIMOTO T: Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J 1990; 4: 2860-7.
77. VAN DEVENTER SJH, BULLER HR, TEN CATE JW, AARDEN LA, HACK EC, STRUK A: Experimental endotoxemia in humans: analysis of cytokines release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-26.
78. REFAELI Y, LEVY DN, WEINER DB: The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc Natl Sci USA 1995; 93: 3621-5.
79. KINO T, DE CASTRO M, KOPP JB, CHROUSOS GP: The human immunodeficiency virus type 1 (HIV-1) vpr gene product represses the transactivating effect of the glucocorticoid receptor and may contribute to the acquired glucocorticoid resistance of AIDS. Section on Pediatric Endocrinology, DEB NICHD. Kidney Disease Section, MDB, NIDDK, NIH, Bethesda, MD, 20892 USA.